Recent advancements in neuroprotection for glaucoma have seen a shift towards multifaceted approaches targeting various aspects of the disease's pathophysiology. Traditional strategies were primarily focused on lowering intraocular pressure (IOP) but emerging trends highlight the importance of preserving retinal ganglion cells (RGCs) and their axons. Novel therapeutics aim to enhance neurotrophic support, reduce excitotoxicity, and mitigate oxidative stress, complementing IOP-lowering therapies for comprehensive management. Stem cell therapies, neurotrophic factors, and gene therapies show promise in promoting RGC survival and axonal regeneration. Additionally, the repurposing of existing drugs, such as calcium channel blockers and anti-inflammatory agents, for neuro-protection in glaucoma underscores the importance of exploring diverse mechanisms. These innovative approaches represent a paradigm shift in glaucoma management, emphasizing the need for a holistic approach targeting both IOP and neuroprotection to preserve vision effectively.
No takes yet. Share an insight, caveat, or question.
Omaka et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: